Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK043 Combined With Osimertinib in EGFR-Mutated NSCLC
NCT07710612Phase 2Not yet recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lumipodlin in non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 30 months and 3 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
lumipodlin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07710612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710612.